Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
Tometich DB, Geiss C, Maconi ML, Chavez M, Hoogland AI, Li X, Nieves-Lopez A, Rodriguez Y, Bryant C, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Hwu P, Khushalani NI, Jim HSL. Tometich DB, et al. Among authors: markowitz j. Support Care Cancer. 2024 May 6;32(6):330. doi: 10.1007/s00520-024-08538-8. Support Care Cancer. 2024. PMID: 38709312
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A. Eroglu Z, et al. Among authors: markowitz j. Cancer. 2023 Jun 1;129(11):1723-1734. doi: 10.1002/cncr.34716. Epub 2023 Mar 4. Cancer. 2023. PMID: 36869646 Free article.
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: markowitz j. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.
Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, Markowitz J, Ebert LM, Brown MP, Tapia-Rico G, Frederick D, Cong X, Serie D, Lindpaintner K, Schwarz F, Boland GM. Pickering C, et al. Among authors: markowitz j. Front Immunol. 2023 Jun 14;14:1187332. doi: 10.3389/fimmu.2023.1187332. eCollection 2023. Front Immunol. 2023. PMID: 37388743 Free PMC article.
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Among authors: markowitz j. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
A metabolic perspective on nitric oxide function in melanoma.
Jimenez J, Dubey P, Carter B, Koomen JM, Markowitz J. Jimenez J, et al. Among authors: markowitz j. Biochim Biophys Acta Rev Cancer. 2024 Jan;1879(1):189038. doi: 10.1016/j.bbcan.2023.189038. Epub 2023 Dec 5. Biochim Biophys Acta Rev Cancer. 2024. PMID: 38061664 Free PMC article. Review.
993 results